All studies
RecruitingNot ApplicableInterventional

Tailoring treatment for HER2-positive early breast cancer

Standard treatment for HER2-positive early breast cancer often involves surgery, chemotherapy, and a targeted drug called trastuzumab for about a year. In many patients, drug treatment given before surgery clears all signs of the cancer. This is known as a complete response. The HER2-RADiCAL trial is exploring whether these patients can safely receive less treatment after their operation. Instead of having a full year of trastuzumab, volunteers receive about six months in total and do not have any further chemotherapy. Receiving less medication could mean fewer hospital visits and a lower chance of unwanted side effects, such as heart problems or extreme tiredness. Researchers want to confirm whether this gentler approach protects against the cancer returning just as well as standard care. All participants are closely monitored for at least five years.

At a glance

Status
Recruiting
Phase
Not Applicable
Sponsor
Institute of Cancer Research
Enrolment target
720
Start
03 Dec 2021
Estimated completion
30 Nov 2027

What is this study about?

Breast cancer cells sometimes have high levels of a protein called HER2, which causes them to grow more quickly. Doctors treat early-stage HER2-positive breast cancer using a combination of chemotherapy and targeted drugs like trastuzumab and pertuzumab before surgery. For many people, these medicines work exceptionally well, destroying all active cancer cells in the breast and nearby lymph nodes by the day of their operation.

Under current standard NHS care, patients still continue taking trastuzumab for a full year after surgery, and some may be offered extra chemotherapy. While this is done to prevent the cancer from coming back, it means months of extra hospital trips and increases the risk of long-term side effects, including strain on the heart.

The HER2-RADiCAL study is looking at whether doctors can safely tailor treatment to each person's response. If tests show your cancer was already completely cleared by your pre-surgery treatment, researchers want to find out whether having just six months of trastuzumab in total—with no extra chemotherapy—is enough to keep you cancer-free.

By carefully reducing treatment for people who respond well, the study hopes to spare patients unnecessary medicines and side effects without lowering their chances of a full cure.

Key takeaways

  • Tests whether six months of targeted therapy is as effective as a full year for early breast cancer.
  • Designed for people whose cancer completely cleared after drug treatment before surgery.
  • Participants avoid extra chemotherapy and additional targeted drugs after their operation.
  • Aims to reduce hospital visits and lower the risk of lasting side effects, such as heart strain.
  • Volunteers receive close monitoring and annual mammograms for at least five years.

Who may be eligible?

This trial is open to women and men aged 16 and over who have been diagnosed with early-stage, HER2-positive breast cancer. To be considered, you must have already received chemotherapy along with the targeted medicines trastuzumab and pertuzumab before having surgery.

A key requirement is that your operation results show what doctors call a "pathological complete response". This means that when the tissue and lymph nodes removed during surgery were examined in the laboratory, no active cancer cells were found.

Your tumour must also have been within specific size limits before your pre-surgery treatment began, with only limited spread to nearby armpit lymph nodes. You must be well enough to continue receiving targeted drug treatment and able to attend routine hospital check-ups.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 16 or over.
  2. I have been diagnosed with early-stage, HER2-positive breast cancer.
  3. I had chemotherapy, trastuzumab, and pertuzumab before my operation.
  4. My surgery tissue showed no remaining active cancer cells (a complete response).
  5. I am well enough to continue receiving targeted drug treatment.
Answer every question to see your result.

What does participation involve?

If you take part, you will receive a shorter course of the targeted drug trastuzumab, lasting for a total of nine treatment cycles (about six months). This includes the doses you already had before your surgery. The drug is given just like normal care, either as a quick injection under the skin or through a drip into a vein. You will not receive any further chemotherapy or pertuzumab after surgery.

Before each treatment cycle, you will meet with your hospital team to check on your general health. You will also have painless heart scans, such as an ultrasound called an echocardiogram, around four and eight months after starting treatment to ensure your heart remains healthy. Other standard preventative treatments, such as radiotherapy or hormone therapy tablets, will continue as planned. Once your medication ends, you will have a yearly mammogram and clinic check-up for at least five years.

Potential risks and benefits

Taking part could lower your risk of short- and long-term side effects, including heart problems, and means fewer hospital appointments. However, having less treatment carries a small possibility that the cancer could be slightly more likely to return, although previous research suggests this risk is very low. An independent safety committee will monitor the trial closely to protect all participants. Taking part is completely voluntary, and you are free to leave the study at any time without it affecting your standard NHS care.

Locations (68)

  • New Victoria Hospital
    Approximate
    Glasgow, Scotland
  • Belfast City Hospital
    Approximate
    Belfast, Northern Ireland
  • The Maidstone Hospital
    City only
    Maidstone, England
  • Royal Free Hospital
    Approximate
    London, England
  • Yeovil District Hospital
    City only
    Yeovil, England
  • Ysbyty Gwynedd
    Unverified
    Bangor, Wales
  • Forth Valley Royal Hospital
    Unverified
    Larbert, Scotland
  • Royal Cornwall Hospital
    Unverified
    Truro, England
  • Poole Hospital
    Unverified
    Poole, England
  • Kent & Canterbury Hospital
    Unverified
    Canterbury, England
  • Christie Hospital
    Unverified
    Manchester, England
  • Medway Maritime Hospital
    Unverified
    Gillingham, England

Common questions

What is HER2-positive breast cancer?

It is a type of breast cancer where the cells have extra HER2 proteins that help the cancer grow. Targeted medicines like trastuzumab work specifically by blocking these proteins.

How is trastuzumab given during the trial?

It is given in the standard way, either as an injection under the skin or through a drip in your arm, usually once every three weeks.

Will I still have radiotherapy or hormone tablets?

Yes. Taking part does not stop you from having other recommended treatments such as radiotherapy, hormone therapy, or bone-strengthening medicines.

Why do I need heart scans?

Trastuzumab can sometimes cause temporary strain on the heart muscle. Routine scans ensure your heart is working normally throughout your care.

What happens if I change my mind about taking part?

You can withdraw from the study at any time. Your medical team will discuss standard treatment options with you, and your ongoing care will continue as normal.

How to find out more

Hannah Johnson

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "Tailoring treatment for HER2-positive early breast cancer…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.